

BMS-983970

Cat. No.: HY-12419 CAS No.: 1584713-87-0

Molecular Formula: $C_{26}H_{26}F_{4}N_{4}O_{3}$

Molecular Weight: 518.5 Target: Notch

Pathway: Neuronal Signaling; Stem Cell/Wnt

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

> -20°C 1 year

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: ≥ 50 mg/mL (96.43 mM)

* "≥" means soluble, but saturation unknown.

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9286 mL	9.6432 mL	19.2864 mL
	5 mM	0.3857 mL	1.9286 mL	3.8573 mL
	10 mM	0.1929 mL	0.9643 mL	1.9286 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (4.82 mM); Suspended solution; Need ultrasonic and warming
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.82 mM); Suspended solution; Need ultrasonic and warming
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.82 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	BMS-983970 is an oral pan-Notch inhibitor for the treatment of multiplecancers $^{[1]}$.
IC ₅₀ & Target	$Notch^{[1]}$
In Vivo	BMS-983970 demonstrates anti-tumor activity in T-cell acute lymphoblastic leukemia (T-ALL) and solid tumor xenograft models ^[1] .

ERENCES							
hvinikumar V. Gavai, et al	Abstract 1643:	: BMS-983970, an c	oral pan-Notch inhibit	or for the treatme	ent of cancer. Cancer R	es October 1, 2014 74; 1	1643.
			een fully validated		lications. For resear		
	Tel: 609-228		Fax: 609-228-5909		ail: tech@MedChemI ion, NJ 08852, USA	Express.com	
		Address, 1 Dee	r r ark br, suite Q, w	ommouth sunct	.ioii, NJ 00032, 03A		

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Page 2 of 2 www.MedChemExpress.com